In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

CNBC’s Jim Cramer delivers his daily Mad Dash.

The company recently wowed investors with clinical trial results.

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

July 6 (Reuters) - Morgan Stanley said the recent weakness in U.S. semiconductor stocks is a sign that the market gains are broadening, with investors likely to turn toward AI "hyperscalers" as well ...

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities ...

Fermenta Biotech's plant-based Vitamin D3 supplement, Vitadee Green, has received FSSAI approval, paving the way for its use in health supplements and food products, addressing the growing demand for ...